clinical trial · NCT07283367
A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.
Hansoh BioMedical R&D Company·phase2·not yet recruiting·n = 502
CRCCohort 1: HS-20110+ Bevacizumab+5-FU/leucovorinCohort 2: HS-20110+Bevacizumab+Oxaliplatin+5-FU/leucovorinCohort 3: HS-20110+Bevacizumab+Oxaliplatin+Capecitabine
brief summary
This is a multicenter, open-label Phase Ib/II clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of the HS-20110 combination therapies in Patients with Advanced Colorectal Cancer. "Rolling 6" design would be used to conduct dose escalation part of this study. This study consists of phase Ib and phase II. After RP2D was determined in phase Ib, then a phase II study will be conducted to further evaluate the efficacy, safety, tolerability, and PK of the HS-20110 combination therapies in Patients with mCRC.
started
Dec 19, 2025
primary completion
Dec 31, 2029
completion
Dec 31, 2029
last updated
Dec 15, 2025
official title
A Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-20110 Combination Therapies in Patients With Advanced Colorectal Cancer.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol